In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Lantheus (LNTH – Research Report), with a price target of $100.00.
David Turkaly has given his Buy rating due to a combination of factors including the recent CEO transition and the company’s strong financial performance. Lantheus’s organized CEO succession appears to be a strategic move with Brian Markison’s extensive experience in the pharmaceutical and oncology sectors, aligning with the company’s focus on therapeutic oncology. This transition, combined with recent deals in the same field, suggests a seamless continuation of the company’s growth trajectory.
Moreover, Lantheus’s financial outlook is particularly promising, with projected sales for the fourth quarter surpassing expectations and an increase in full-year revenue guidance for one of its leading products. The company’s robust financial profile is bolstered by its leadership in radiopharmaceuticals, strategic acquisitions, and partnerships. Considering these aspects, Turkaly views Lantheus as a sustainable growth leader in the MedTech sector, with a pipeline that promises future upside potential without relying on the new therapeutic opportunities in the near term. The valuation of the stock as inexpensive relative to its peers, coupled with a solid price target, underscores the Buy rating.
In another report released on January 11, JonesTrading also maintained a Buy rating on the stock with a $114.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lantheus (LNTH) Company Description:
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More on LNTH:
- Lantheus Announces CEO Succession Plan
- Lantheus announces acceptance of its first-to-file ANDA for generic LUTATHERA
- Perspective Therapeutics enters strategic agreements with Lantheus
- Lantheus expands radiopharmaceutical oncology pipeline via agreements
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
